Equities research analysts predict that CorMedix Inc (NASDAQ:CRMD) will announce sales of $190,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for CorMedix’s earnings. The lowest sales estimate is $80,000.00 and the highest is $300,000.00. CorMedix reported sales of $370,000.00 during the same quarter last year, which indicates a negative year over year growth rate of 48.6%. The business is scheduled to issue its next earnings report on Wednesday, November 13th.

According to Zacks, analysts expect that CorMedix will report full year sales of $460,000.00 for the current financial year, with estimates ranging from $430,000.00 to $490,000.00. For the next fiscal year, analysts anticipate that the business will report sales of $12.28 million, with estimates ranging from $9.89 million to $14.67 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow CorMedix.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.13 million.

Shares of CorMedix stock traded up $0.21 during trading hours on Tuesday, hitting $8.46. The company’s stock had a trading volume of 6,071 shares, compared to its average volume of 459,986. The business has a 50 day moving average price of $8.27 and a two-hundred day moving average price of $7.32. CorMedix has a 12-month low of $2.64 and a 12-month high of $13.70.

About CorMedix

CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.

Featured Article: What is Net Asset Value (NAV)?

Get a free copy of the Zacks research report on CorMedix (CRMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.